Weissella confusa MW051433 and Levilactobacillus brevis MW362788 of human milk origin possess antioxidant competency: In vivo evidence

Abstract

Consumption of high-fat diet (HFD) is directly associated with oxidative stress (OS), a root cause of metabolic disorders while probiotics have been recently recognized to play important role in OS management. The current study describes the antioxidant potential of well characterized and least explored probiotics, Levilactobacillus brevis MW362788 and Weissella confusa MW051433 isolated from human milk. Wistar rats were exposed to HFD to induce OS and treated with W. confusa MW051433, L. brevis MW 362788 and their mixture. W. confusa MW051433 treatment led to amelioration of OS as depicted by improvement in Malondialdehyde (MDA), Total oxidant status (TOS), Total antioxidant status (TAS), Superoxide dismutase (SOD), Catalase (CAT), Glutathione-S-transferase (GST), and Glutathione (GSH) in serum, liver, kidney, and brain. The L. brevis MW362788 administration restored MDA, SOD (serum, liver, kidney), TOS (serum, kidney), TAS (serum, liver, kidney, brain), GST (liver), GSH (kidney, brain) but could not influence CAT activity in any organ. While administration of their mixture could customize MDA, TAS (serum, liver, kidney, brain), TOS, SOD, CAT (serum, liver, kidney), GST (serum, liver), and GSH (serum, kidney, brain). The OS modulation was strain specific and the promising antioxidant behavior of W. confusa MW051433 signatures its bio therapeutic potential.